Medical Digest & Congress Report

Professor Giampaolo Bianchini shares his insights on the DESTINY-Breast12 study. Video: https://medicaldigest.org/scientific-contents/interview:substantial-and-durable-overall-and-intracranial-activity-trastuzumab-deruxtecan-previously-treated-her2-positive-mbc-including-large-cohort-patients-brain-metastases

Professor Petros Grivas shares his insights on the NIAGARA study. Video: https://medicaldigest.org/scientific-contents/interview:randomized-phase-3-trial-neoadjuvant-durvalumab-plus-chemotherapy-followed-radical-cystectomy-and-adjuvant-durvalumab-muscle-invasive-bladder-cancer

Professor Petros Grivas shares his insights on the AMBASSADOR study. Video: https://medicaldigest.org/scientific-contents/interview:adjuvant-pembrolizumab-prolongs-dfs-among-patients-high-risk-muscle-invasive-urothelial-carcinoma

Professor Yelena Janjigian shares his thoughts on biomarker selected strategies and immunotherapy change the landscape of upper GI tumor treatment from ESMO2024. Video: https://medicaldigest.org/scientific-contents/interview:biomarker-selected-strategies-and-immunotherapy-change-landscape-upper-gi-tumor-treatment

Professor Dirk Arnold shares his thoughts on lower gastrointestinal news from ESMO2024. Video: https://medicaldigest.org/scientific-contents/interview:rise-cancer-young-adults-lower-gi-news-esmo2024

Professor Federica Di Nicolantonio shares his thoughts on the Rome and GigaPath trials and the importance of moving towards molecular and AI-driven oncology. Video: https://medicaldigest.org/scientific-contents/interview:eyes-future-moving-towards-molecular-and-ai-driven-oncology

Professor Petra Tesarova shares his thoughts on CDK 4-6 inhibitors in early breast cancer. Video: https://medicaldigest.org/scientific-contents/interview:incorporating-novel-treatment-insights-er-early-bc-patients-report-esmo2024

Professor Davide Melisi shares his thoughts on novel targeted therapies for pancreatic cancer. Video: https://medicaldigest.org/scientific-contents/interview:novel-targeted-therapies-pancreatic-cancer

Professor David Sebag-Montefiore shares his thoughts on systemic therapy for organ preservation and the findings from the NO-CUT trial were presented at the ESMO Congress 2024. The study explored the efficacy of more aggressive initial treatment known as total neoadjuvant therapy followed by non-operative management in patients with mismatch repair proficient locally advanced rectal cancer. Video:...

Professor Andrea Botticelli presented the Rome trial results at ESMO 24 Presidential Session. Patients with advanced cancers receiving tumor-agnostic treatments based on the recommendations of a molecular tumor board had significantly better response rates and lived longer without the disease progressing than those receiving the standard of care in the ROME trial. Video: https://medicaldigest.org/...

Professor Aristotelis Bamias shares his thoughts on genitourinary tumours highlights of the ESMO 2024 Congress. Video: https://medicaldigest.org/scientific-contents/interview:genitourinary-tumours-non-prostate-highlights-esmo-2024-congress

Professor Jianjun Zhang shares his thoughts on lung cancer screening and prevention. Video: https://medicaldigest.org/scientific-contents/interview:lung-cancer-interception-new-approaches-lung-cancer-screening-and-prevention

Professor Domenica Lorusso presented the overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer. Video: https://medicaldigest.org/scientific-contents/interview:pembrolizumab-plus-chemoradiotherapy-high-risk-locally-advanced-cervical-cancer-overall-survival-results...

Professor Josep Llovet discusses the results of LEAP-012 Study which he presented at ESMO 2024. Video: https://medicaldigest.org/scientific-contents/interview:leap-012-study-transarterial-chemoembolization-or-without-lenvatinib-pembrolizumab-intermediate-stage-hepatocellular-carcinoma

Professor Silke Gillessen discussing results from STAMPEDE trial assessing the addition of metformin to ADT for patients with mHSPC. Video: https://medicaldigest.org/scientific-contents/interview:adding-metformin-adt-patients-mhspc-overall-survival-results-multi-arm-multi-stage-randomized-platform-trial-stampede

Professor Silke Gillessen presented new results from the PEACE-3 trial at the 2024 ESMO conference. This study indicates that combining Enzalutamide with Radium223 significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases over Enzalutamide alone. Video: https://medicaldigest.org/scientific-contents/interview:peace-...

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC. Video: https://medicaldigest.org/scientific-contents/interview:neoadjuvant-pembrolizumab-or-placebo-plus-chemotherapy-followed-adjuvant-pembrolizum...

Professor Dominik P. Modest shares his thoughts on POD1UM-303/InterAACT 2 study, which are potentially practice-changing findings in squamous cell carcinoma of the anal canal. Video: https://medicaldigest.org/scientific-contents/interview:pod1um-303interaact-2-potentially-practice-changing-findings-scac-report-esmo2024

Professor Tony S.K. Mok shares his thoughts on setting a new benchmark for ALK+ aNSCLC targeted therapy. Video: https://medicaldigest.org/scientific-contents/interview:setting-new-benchmark-alk-ansclc-targeted-therapy-report-esmo2024

Professor Ann Partridge shares his thoughts on breast cancer, early stage highlights of the ESMO 2024 Congress. Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-early-stage-highlights-esmo-2024-congress

Professor Remi Nout shares his thoughts on the interim results of the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial that were presented during the ESMO Congress 2024. Video: https://medicaldigest.org/scientific-contents/interview:adjuvant-pembrolizumabchemotherapy-misses-dfs-end-point-high-risk-endometrial-cancer-benefits-dmmr-subgroup

Professor Remi Nout shares his thoughts on the treatment of cervical cancer in 2024 in the light of KEYNOTE-A18 study. Video: https://medicaldigest.org/scientific-contents/interview:treatment-cervical-cancer-2024-highlight-keynote-a18-study

Prof. Michael Böhm explains how SGLT-2 inhibitors became a strong pillar of treatment in HFrEF and HFpEF patients. Their antidiabetic effect and kidney protection make them a widely used tool in cardiovascular diseases. We learn where GLP-1 agonists stand in cardiovascular risk protection and how beneficial they are in overweight HFpEF patients. The new mineralocorticoid receptor antagonists (MRAs...

Prof. Carlos Robalo Cordeiro, immediate Past-President of the ERS shares his thoughts on the highlights of ERS 2024. Video: https://medicaldigest.org/scientific-contents/interview:highlihts-ers-2024-presidents-perspective

Prof. Michael Kreuter co-chaired a very interesting session at this years ERS congress on novelties in the treatement of interstitial lung diseases and pulmonary fibrosis. Video: https://medicaldigest.org/scientific-contents/interview:why-idiopathic-pulmonary-fibrosis-not-so-idiopathic-report-ers2024